Pure Global

Comparison of Rimegepant and Placebo for Pain in IBS - Trial NCT06221111

Access comprehensive clinical trial information for NCT06221111 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06221111
Phase 4
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06221111
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Comparison of Rimegepant and Placebo for Pain in IBS
Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study

Study Focus

Irritable Bowel Syndrome

Rimegepant 75 MG [Nurtec]

Interventional

drug

Sponsor & Location

Mayo Clinic

Rochester, United States of America

Timeline & Enrollment

Phase 4

Apr 15, 2024

Jun 01, 2025

24 participants

Primary Outcome

abdominal pain

Summary

The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain
 scores in participants with non-constipation IBS.

ICD-10 Classifications

Irritable bowel syndrome
Other and unspecified irritable bowel syndrome
Irritable bowel syndrome with mixed bowel habits [IBS-M]
Irritable bowel syndrome with predominant constipation [IBS-C]
Irritable bowel syndrome with predominant diarrhoea [IBS-D]

Data Source

ClinicalTrials.gov

NCT06221111

Non-Device Trial